ClinicalTrials.gg

Program

dalmelitinib

Also written as “HS-10241” and “HS-10241+ Almonertinib”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasms · Carcinoma, led by 2 companies.

Furthest: phase 3, since Oct 24, 20237 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group62 open or runningphase 3since Oct 24, 2023Nov 11, 2016none ahead
Jiangsu HengRui Medicine10 open or runningphase 1since Apr 29, 2016Apr 29, 2016none ahead
  • Named in Hansoh Pharmaceutical Group’s own pipeline as Dalmelitinib (HS-10241), phase 4, as of Aug 26, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 29, 2016First study: phase 1 study in NeoplasmsNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT02759640 · 7 enrolled · Australia
  2. Nov 11, 2016Hansoh Pharmaceutical Group's first study: phase 1 study in CarcinomaNew to Hansoh Pharmaceutical GroupHansoh Pharmaceutical Group · NCT02977364 · 50 enrolled · China
  3. Jul 18, 2017Phase 1 study in Advanced CancerHansoh Pharmaceutical Group · NCT03243643 · 80 enrolled · China
  4. Apr 27, 2020Phase 1 study in Solid TumorHansoh Pharmaceutical Group · NCT04477057 · 30 enrolled · China
  5. Jun 14, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT05430386 · 174 enrolled · China
  6. Oct 24, 2023Phase 3 study in Carcinoma, Non-Small-Cell LungHansoh Pharmaceutical Group · NCT06110663 · 314 planned
  7. Dec 23, 2024Phase 1 study in Advanced Non-small Cell Lung CancerHansoh Pharmaceutical Group · NCT06823245 · 32 planned

TargetBeta

“An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), with potential antineoplastic activity. Upon oral administration, HS-10241 targets and binds to the c-Met protein, prevents c-Met phosphorylation and disrupts c-Met-dependent signal…”NCIt, read by Claude
“An orally bioavailable small molecule inhibitor of the oncoprotein c-Met (hepatocyte growth factor receptor; HGFR), ”NCIt, by rule

Other programs on MET

ProgramCompanyFurthest phaseStudies
cabozantinibruleExelixisphase 436
CrizotinibrulePfizerphase 431
telisotuzumab adizutecanAbbViephase 318
zanzalintinibruleExelixisphase 317
amivantamabruleJohnson & Johnsonphase 316
vebreltinibrulebeijing-pearl-biotechnology-limited-liability-companyphase 39
glumetinibruleHaihe Biopharmaphase 38
vilzemetkibSino Biopharmaceuticalphase 38
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
HS-20117Hansoh Pharmaceutical Groupphase 33
SHR-1826Jiangsu HengRui Medicinephase 27
pamvatamigruleBetta Pharmaceuticalsphase 25

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06823245Advanced Non-small Cell Lung Cancer1Not yet recruitingHansoh Pharmaceutical GroupJul 31, 202532
NCT06110663Carcinoma, Non-Small-Cell Lung3Not yet recruitingHansoh Pharmaceutical GroupDec 30, 2024314
NCT05430386Carcinoma, Non-Small-Cell Lung · China1UNKNOWNHansoh Pharmaceutical GroupDec 31, 2023174
NCT04477057Solid Tumor · China1UNKNOWNHansoh Pharmaceutical GroupDec 31, 202030
NCT03243643Advanced Cancer · China1UNKNOWNHansoh Pharmaceutical GroupJul 201980
NCT02977364Carcinoma · China1UNKNOWNHansoh Pharmaceutical GroupNov 201850
NCT02759640Neoplasms · Australia1CompletedJiangsu HengRui MedicineMar 20187

How it is read

Names in the registry

  • “HS-10241”, 6 entries
  • “HS-10241+ Almonertinib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.